BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mishra I, Xie WR, Bournat JC, He Y, Wang C, Silva ES, Liu H, Ku Z, Chen Y, Erokwu BO, Jia P, Zhao Z, An Z, Flask CA, He Y, Xu Y, Chopra AR. Protein tyrosine phosphatase receptor δ serves as the orexigenic asprosin receptor. Cell Metab 2022:S1550-4131(22)00084-5. [PMID: 35298903 DOI: 10.1016/j.cmet.2022.02.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Wu Q, Gao Z, Yu X, Wang P. Dietary regulation in health and disease. Sig Transduct Target Ther 2022;7. [DOI: 10.1038/s41392-022-01104-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Mishra I, Chopra AR. Overexpression and ELISA-based detection of asprosin in cultured cells and mice. STAR Protoc 2022;3:101762. [PMID: 36240062 DOI: 10.1016/j.xpro.2022.101762] [Reference Citation Analysis]
3 Kerslake R, Sisu C, Panfilov S, Hall M, Khan N, Jeyaneethi J, Randeva H, Kyrou I, Karteris E. Differential Regulation of Genes by the Glucogenic Hormone Asprosin in Ovarian Cancer. J Clin Med 2022;11:5942. [PMID: 36233808 DOI: 10.3390/jcm11195942] [Reference Citation Analysis]
4 Xu Y, Zhu H, Li W, Chen D, Xu Y, Xu A, Ye D. Targeting adipokines in polycystic ovary syndrome and related metabolic disorders: from experimental insights to clinical studies. Pharmacology & Therapeutics 2022. [DOI: 10.1016/j.pharmthera.2022.108284] [Reference Citation Analysis]
5 Liu L, Liu Y, Huang M, Zhang M, Zhu C, Chen X, Bennett S, Xu J, Zou J. The Effects of Asprosin on Exercise-Intervention in Metabolic Diseases. Front Physiol 2022;13:907358. [DOI: 10.3389/fphys.2022.907358] [Reference Citation Analysis]
6 Hu Y, Kang Q, Chen C, Guo L, Chen J. Increased plasma asprosin levels are associated with overeating and loss of control in drug-free bulimia nervosa. Eat Weight Disord 2022. [PMID: 35768687 DOI: 10.1007/s40519-022-01431-5] [Reference Citation Analysis]